Skip to search formSkip to main contentSkip to account menu

Imnovid

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pomalidomide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
  • O. Fuchs
  • Cardiovascular & Haematological Disorders - Drug…
  • 2019
  • Corpus ID: 46897258
Thalidomide and its derivatives (lenalidomide, pomalidomide, avadomide, iberdomide hydrochoride, CC-885 and CC-90009) form the… 
Review
2017
Review
2017
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma
Pomalidomide (Imnovid®; Pomalyst®), an analogue of thalidomide, is an immunomodulatory agent, with several mechanisms of action… 
Review
2017
Review
2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single…
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA… 
2017
2017
PHARMACOECONOMIC EVALUATION OF POMALIDOMIDE (IMNOVID) FOR THE TREATMENT OF RECURRENT AND REFRACTORY MULTIPLE MYELOMA
2016
2016
Pharmacoeconomic evaluation of pomalidomide (imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide…
2016
2016
Pomalidomida (▼ Imnovid): riesgo de reactivación de la hepatitis B asociado a su uso
Review
2014
Review
2014
POMALIDOMID – nowy immunomodulujący lek w terapii szpiczaka plazmocytowego
Review
2014
Review
2014
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several… 
2013
2013
Produkt Imnovid
Imnovid® ist ein neuer Wirkstoff aus der Klasse der IMiDs® (Immunmodulatoren). Mit einer Standarddosierung von 4 mg (orale Gabe… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)